Quince Therapeutics (QNCX) Accumulated Expenses (2018 - 2026)
Quince Therapeutics (QNCX) posted quarterly Accumulated Expenses of $871000.0 for Q1 2026, down 83.71% year-over-year from $5.3 million in Q1 2025, and down 91.79% quarter-over-quarter from $10.6 million in Q4 2025.
Quince Therapeutics (QNCX) Accumulated Expenses (2018 - 2026) Analysis & Trends
Quince Therapeutics' Accumulated Expenses history runs 9 years deep, the most recent figure standing at $871000.0 for Q1 2026.
- In Q1 2026, Accumulated Expenses fell 83.71% year-over-year to $871000.0; the TTM figure through Mar 2026 stood at $871000.0 (down 83.71% YoY), while the FY2025 annual figure was $10.6 million, up 327.4% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $871000.0, down from $10.6 million in the prior quarter.
- The five-year high for Accumulated Expenses was $10.6 million in Q4 2025, with the low at $457000.0 in Q1 2023.
- The 5-year median for Accumulated Expenses is $2.9 million (2024), against an average of $3.5 million.
- The sharpest annual moves came in 2022 and 2025: Accumulated Expenses tumbled 92.87% in 2022, then soared 327.4% in 2025.
- Quince Therapeutics' Accumulated Expenses stood at $2.5 million in 2022, then soared by 37.49% to $3.4 million in 2023, then retreated by 27.76% to $2.5 million in 2024, then jumped by 327.4% to $10.6 million in 2025, then tumbled by 91.79% to $871000.0 in 2026.
- Business Quant data shows QNCX's Accumulated Expenses at $871000.0 in Q1 2026, $10.6 million in Q4 2025, and $5.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Quince Therapeutics | 203.43 Mn | 203.43 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 871,000.00 |
| Dec 31, 2025 | 10.61 Mn |
| Sep 30, 2025 | 5.12 Mn |
| Jun 30, 2025 | 5.71 Mn |
| Mar 31, 2025 | 5.35 Mn |
| Dec 31, 2024 | 2.48 Mn |
| Sep 30, 2024 | 3.80 Mn |
| Jun 30, 2024 | 2.92 Mn |
| Mar 31, 2024 | 1.37 Mn |
| Dec 31, 2023 | 3.44 Mn |
| Sep 30, 2023 | 1.84 Mn |
| Jun 30, 2023 | 1.60 Mn |
| Mar 31, 2023 | 457,000.00 |
| Dec 31, 2022 | 2.50 Mn |
| Sep 30, 2022 | 804,000.00 |
| Jun 30, 2022 | 4.08 Mn |
| Mar 31, 2022 | 5.98 Mn |
| Dec 31, 2021 | 9.31 Mn |
| Sep 30, 2021 | 11.27 Mn |
| Jun 30, 2021 | 11.34 Mn |